xm:罗成
xb:男
zc:研究员
xl:博士
dh:
cz:
dzyj:cluo@simm.ac.cn
grzy:
zjlb:研究员；****；新药；
zw:课题组长
txdz:上海市祖冲之路555号
grjj:罗成，博士，中科院上海药物所研究员，博士生导师，获国家****基金资助，入选科技部创新领军人才，上海市优秀学科带头人。研究领域：药物设计、分子药理学和化学生物学。罗成开展多学科交叉研究，针对重大疾病相关通路/靶标，运用药物设计技术，开展基于药物化学生物学的靶标新功能发现、药物作用机理研究和创新药物研发。发现了多个重要天然产物或内源代谢的作用靶标，揭示了多个重要靶标的调控机制；发现一批具有开发前景的先导化合物（7类以上为该靶标世界首次发现），三个化合物进入了临床前评价。共发表SCI论文180余篇，总影响因子（IF）约1200，论著被引用约5600次。近5年来，研究结果在Nature、Cancer Cell、Nature Chem、Adv Mater、Adv Sci、JACS、PNAS、Nucleic Acid Res和J Med Chem等国际著名杂志发表通讯、共同通讯或第一作者论文71篇。申请专利42项（美国专利1项、PCT 8项），获得授权专利5项（五项成果已经完成转化）；主持“863”课题、基金委重大研究计划重点课题、****等项目10余项。培养及联合培养研究生40余名，部分学生已经入选中科院国内人才计划，部分学生在哈佛大学、宾夕法尼亚大学、欧洲分子生物学中心从事博士后研究等。

教育经历：

9/2001-7/2004 中国科学院上海药物研究所有机化学 博士

9/1998-7/2001 复旦大学化学系物理化学 硕士

9/1990-7/1994 福州大学化学系化学（结构化学） 学士

yjfx:主要研究方向为药物设计与化学生物学。运用药物设计，生化、结构生物学和药理学等多学科交叉手段，开展基于疾病相关新靶标的功能发现、药物作用机理研究和重要天然产物或内源代谢的作用靶标发现，探索化学探针针对新靶标的调控机制，为新靶标、新机制的创新药物奠定活性物质或药物靶标基础。

dblz:1. Zhongya Sun, Hao Zhang, Yuanyuan Zhang, Liping Liao, Wen Zhou, Fengcai Zhang, Fulin Lian, Jing Huang, Pan Xu, Rukang Zhang, Wenchao Lu, Mingrui Zhu, Hongru Tao, Hong Ding, Shijie Chen, Liyan Yue, Bing Zhou, Naixia Zhang, Minjia Tan, Chuanpeng Liu*, Bo Liu*, Kaixian Chen, Hualiang Jiang, Yongjun Dang*, and Cheng Luo*. Covalent inhibitors allosterically block the activation of Rho family proteins and suppress cancer cells invasion. Adv Sci. 2020 May 13;7(14):**.

2. Zizhou Li, Senhao Xiao,Yaxi Yang, Chao Chen, Tian Lu, Zhifeng Chen,Hualiang Jiang, Shijie Chen, Cheng Luo* and Bing Zhou*. Discovery of 8-Methyl-pyrrolo [1,2-a]pyrazin-1(2H)-one Derivatives as Highly Potent and Selective Bromodomain and Extra-terminal (BET) Bromodomain Inhibitors. J Med Chem 2020, accepted.

3. Yaxi Yang, Rukang Zhang, Zhaojun Li, Lianghe Mei, Shili Wan, Hong Ding, Zhifeng Chen, Jing Xing, Hualiang Jiang, Mingyue Zheng*, Cheng Luo* and Bing Zhou*, Artificial Intelligence-Assisted Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP HAT Inhibitors. J Med Chem. 2020;63(3):1337-1360

4. Fu T, Liu L, Yang QL, Wang Y, Xu P, Zhang L, Liu S, Dai Q, Ji Q, Xu GL, He C, Luo C*, Zhang L*. Thymine DNA glycosylase recognizes the geometry alteration of minor groove induced by 5-formylcytosine. Chem Sci 2019;;10(31):7407-7417.

5. Ye F, Huang J, Wang H*, Luo C*, Zhao K*. Targeting epigenetic machinery: Emerging novel allosteric inhibitors. Pharmacol Ther. 2019;204:107406..

6. Peng J, Li J, Huang J, Xu P, Huang H, Liu Y, Yu L, Yang Y, Zhou B, Jiang H, Chen K, Dang Y, Zhang Y*, Luo C*, Li G*.p300/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization. Theranostics. 2019;9(26):8344-8361

7. Shi Chen, Rafai Wiewiora, Fanwang Meng, Hao Hu, Junyi Wang, Gil Blum, Robert Skene, Jian Jin, Yunjun George Zheng, Peter Brown, Cheng Luo*, John Chodera*, Minkui Luo*, The Dynamic Conformational Landscapes of the Protein Methyltransferase SETD8. ELife 2019;8. pii: e45403

8. Bai-Nan Zheng, Shi-Jie Chen, Chen-Hong Ding, Jifeng Feng, Wen-Ping Xu, Ling Yan Cai, Chang-Peng Zhu, Kongkai Zhu, Wenhu Duan, Jingwei Shao, Xin Zhang, Cheng Luo*, Wei-Fen Xie*. Targeting PRMT5 Inhibits the Malignancy of Hepatocellular Carcinoma through Promoting the Transcription of HNF4α. Theranostics, 2019;9(9):2606-2617

9. Jinbao Zhang, Shenghai Chang, Pan Xu, Miao Miao, Hangjun Wu, Youyi Zhang, Tongtong Zhang, Han Wang, Jilin Zhang, Chun Xie, Nan Song, Cheng Luo*, Xing Zhang*, Shujia Zhu*. Structural basis of the proton sensitivity of human GluN1/GluN2A NMDA receptors. Cell Rep. 2018 Dec 26;25(13):3582-3590

10. Chen-Hong Ding, Liang-Zhi Wen, Shi-Jie Chen, Chuan Yin, Kai Ding, Shu-Juan Lei, Jin-PeiLiu, Fei-Chen, Jin He, Kai-xian Chen, Hua-liang Jiang, Xin Zhang, Cheng Luo*, Wei-Fen Xie*. The HNF1α-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1. Molecular Cancer 2018; Feb 21;17(1):63.

11. Jiangmei Li, Zhen Gao, Dan Zhao, Lunfeng Zhang, Xinhua Qiao, Yingying Zhao, Hong Ding, Panpan Zhang, Junyan Lu, Jia Liu, Hualiang Jiang, Cheng Luo* and Chang Chen*. PI-273, a substrate-competitive, specific small molecule inhibitor of PI4KIIα, inhibits the growth of breast cancer cells. Cancer Research. 2017 Nov 15;77(22):6253-6266

12. Ruifeng Mao, Jingwei Shao, Kongkai Zhu, Yuanyuan Zhang, Hong Ding, Chenhua Zhang, Zhe Shi, Hualiang Jiang, Dequn Sun*, Wenhu Duan* and Cheng Luo*. Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization. Journal of Medicinal Chemistry. 2017;60:6289-304.

13. Chen Wang, Hao Jiang, Jia Jin, Yiqian Xie, Zhifeng Chen, Hao Zhang, Fulin Lian, Yu-Chih Liu, Chenhua Zhang, Hong Ding, Shijie Chen, Naixia Zhang, Yuanyuan Zhang*, Hualiang Jiang, Kaixian Chen, Fei Ye*, Zhiyi Yao* and Cheng Luo*. Development of Potent Type I Protein Arginine Methyltransferase (PRMT) Inhibitors of Leukemia Cell Proliferation. Journal of Medicinal Chemistry. 2017.

14. Yulan Wang, Linjuan Li, Bidong Zhang, Jing Xing, Shijie Chen, Wei Wan, Yakai Song, Hao Jiang, Hualiang Jiang, Cheng Luo* and Mingyue Zheng*. Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (SAM)-Dependent Methyltransferase Family. Journal of Medicinal Chemistry. 2017;60:2026-36.

15. Junyan Lu, Chenxiao Jianga, Xiaojing Lia, Lizhi Jiang, Zengxia Li, Tilman Schneider-Poetsch, Kunqian Yu, Jun O. Liu, Hualiang Jiang, Cheng Luo*, Yongjun Dang*. The Inter-domain Linker of eIF4AI Regulates ATP Hydrolysis Coupled Duplex Unwinding, Nucleic Acids Res. 2015 Oct 12. pii: gkv1033.

16. Fanwang Meng, Sufang Cheng, Hong Ding, Shien Liu, Ying Liu, Kongkai Zhu, Shijie Chen, Junyan Lu, Yiqian Xie, Linjuan Li, Rongfeng Liu, Zhe Shi, Yu Zhou, Yu-Chih Liu, Mingyue Zheng, Hualiang Jiang, Wencong Lu*, Hong Liu*, and Cheng Luo*. Discovery and optimization of novel, selective histone methyltransferase SET7 inhibitors by pharmacophore- and docking-based virtual screening. J Med Chem 2015 Oct 22;58(20):8166-81.

17. Lulu Hu, Junyan Lu, Jingdong Cheng, Qinhui Rao, Ze Li, Haifeng Hou, Zhiyong Lou, Lei Zhang, Wei Li, Wei Gong, Mengjie Liu, Chang Sun, Xiaotong Yin, Jie Li, Xiangshi Tan, Pengcheng Wang, Yinsheng Wang, Dong Fang, Qiang Cui, Pengyuan Yang, Chuan He, Hualiang Jiang, Cheng Luo* and Yanhui Xu*, Structural Insight into Substrate Preference for TET-mediated Oxidation. Nature 2015 Nov 5; 527(7576): 118-22.

18. Xiangqian Kong, Jian Liu, Lianchun Li, Liyan Yue, Lihong Zhang, Hualiang Jiang, Xin Xie*, Cheng Luo*, Functional Interplay Between the RK motif and Linker Segment Dictates Oct4-DNA Recognition, Nucleic Acids Res 2015;43(9):4381-92.

19. Jun-Hang Jiang, Can-Hui Zheng*, Kongkai Zhu, Jia Liu, Nan-Nan Sun, Chong-Qing Wang, Hualiang Jiang, Ju Zhu,* Cheng Luo*, and You-Jun Zhou*, Quantum Chemistry Calculation-Guided Structural Optimization of Combretastatin A-4-like Tubulin Polymerization Inhibitors: Improved Stability and Biological Activity, J Med Chem 2015;58(5):2538-46.

20. Yue Huang, Jingli Yan, Qi Li, Jiafei Li, Shouzhe Gong, Hu Zhou, Jianhua Gan, Hualiang Jiang, Gui-Fang Jia*, Cheng Luo*, and Cai-Guang Yang* Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res 2015; 43(1):373-84

jyjl:9/2001-7/2004国科学院上海药物研究所有机化学 博士